A milestone in automated autologous CAR-T production
Cellares and Cabaletta Bio have formalized a 10-year commercial supply agreement, marking a significant shift in the production of investigational therapies. The partnership focuses on the automated manufacturing of rese-cel, a chimeric antigen receptor T-cell (CAR-T) therapy designed to target autoimmune diseases. This collaboration aims to secure long-term capacity and predictability in supply to meet the rising global demand for these advanced treatments.
Advanced platforms and operational efficiency The agreement leverages Cellares’ “Cell Shuttle” platform, which holds the distinction of being the first cell therapy manufacturing technology to receive the FDA’s Advanced Manufacturing Technology designation. Key advantages of this automated approach include:
-
Enhanced Throughput: The system offers up to ten times the productivity of conventional contract manufacturing methods.
-
Proven Performance: Initial doses produced via the Cell Shuttle successfully met all clinical specifications and were delivered to patients on schedule.
-
Commercial Scalability: The infrastructure is designed to produce thousands of batches annually, ensuring consistent quality while maintaining an accessible cost structure.
Broadening the scope from Oncology to Autoimmune diseases While autologous CAR-T therapies have traditionally been utilized in oncology, their application in autoimmune diseases addresses patient populations that are significantly larger than those with blood cancers. By securing a decade-long manufacturing commitment, Cabaletta Bio positions itself to meet large-scale commercial requirements. This move represents a fundamental transition in the industry from manual, labor-intensive processes to high-throughput, automated industrial production.